Synthetic biology research, cell therapy manufacturing, cell banking, technology transfer, and dedicated project teams — engineered to work together, all under one roof in the Bay Area.
Synthetic biology research, machine-learning sequence optimization, and proprietary tools — cell-specific promoters, kill switches, targeting/detargeting molecules.
End-to-end autologous & allogeneic workflows — CAR/TCR-T, NK, Treg, iPSC, in-vivo gene therapy. Multiple expansion platforms tuned to your modality.
Lentiviral & gamma-retroviral vector manufacturing — the engine for ex-vivo cell therapy and in-vivo gene therapy. Adherent (2–20 L) and suspension GMP (50–200 L) with stable producer cell lines.
Engineering, Master, and Working cell bank generation — adherent & suspension platforms. Full characterization, qualified storage, scale-up as needed.
Knowledge transfer treated as a discipline, not a checkbox. Structured gap assessments, engineering runs, on-the-floor MSAT — development to GMP in ~6 months.
Dedicated PMO, transparent Gantt charts, cloud-based data exchange, routine technical and quality reviews. One accountable team across SynBio, PD, Manufacturing, AD, and QC.
